"... and a weak ASX that lets companies get away with a lack of transparency in reporting their trial results."
The ASX has guidelines for reporting clinical trial results, and MSB consistently ignores them. The most recent example is the CHF results where they have not reported either the primary or secondary endpoint results - but reported on post hoc results that were not listed as either primary or secondary!
I was always worried about covid-ARDS. It was a typical "cheap and dirty" approach based on no pre-clinical data, and built on assumptions it worked in COPD (BTW, it didn't!). My concerns related to the hype around the Mt Sinai results, which were compared not to the experience at Mt Sinai (which presumably would have been good to excellent) but to some undisclosed hospitals which clearly had a poor experience.
But it seems, like a few other biotechs, MSB found it difficult to resist jumping on the covid bandwagon - to the detriment of their shareholders (of which I was one).
The whole sorry saga just highlights a continuing lack of transparency - a trait unfortunately not just confined to MSB in this sector.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Update on COVID-19 ARDS Trial
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-386
-
-
- There are more pages in this discussion • 690 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
MSB (ASX) Chart |